{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:53:59Z","timestamp":1772826839895,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.tips.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T10:16:07Z","timestamp":1497089767000},"page":"667-668","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Potential of Ranibizumab in Corneal Neovascularization"],"prefix":"10.1016","volume":"38","author":[{"given":"Marianne L.","family":"Shahsuvaryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2017.05.004_bib0005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajo.2006.05.061","article-title":"Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases","volume":"142","author":"Kaiser","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0010","first-page":"625","article-title":"Host immune cellular reactions in corneal neovascularization","volume":"9","author":"Abdelfattah","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjo.2011.204701","article-title":"Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable","volume":"96","author":"Cursiefen","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0020","first-page":"444","article-title":"Corneal neovascularization and biological therapy","volume":"8","author":"Voiculescu","year":"2015","journal-title":"J. Med. Life"},{"key":"10.1016\/j.tips.2017.05.004_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.tips.2017.05.004_bib0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/jop.2016.0094","article-title":"Differential effects of bevacizumab, ranibizumab, and aflibercept on the viability and wound healing of corneal epithelial cells","volume":"32","author":"Kang","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2017.05.004_bib0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1755-3768.2012.02525.x","article-title":"Topical ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis","volume":"92","author":"Bucher","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5301\/ejo.5000391","article-title":"The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model","volume":"24","author":"Liarakos","year":"2014","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0045","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.tips.2017.05.004_bib0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3341\/kjo.2013.27.4.235","article-title":"The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study","volume":"27","author":"Kim","year":"2013","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3341\/kjo.2014.28.2.177","article-title":"Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment","volume":"28","author":"Ahn","year":"2014","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.tips.2017.05.004_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/pr4040047","article-title":"The influence of viscosity on the static and dynamic properties of PS-PEO covered emulsion drops","volume":"4","author":"Damith","year":"2016","journal-title":"Processes"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717301128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717301128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T20:54:38Z","timestamp":1535748878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614717301128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0165614717301128"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2017.05.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}